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Objective: To provide an estimate of the effect of interventions on comorbid depres-
sive	disorder	(MDD)	or	subthreshold	depression	in	type	1	and	type	2	diabetes.
Methods: Systematic	 review	and	meta-analysis.	We	searched	PubMed,	PsycINFO,	
Embase,	 and	 the	Cochrane	Library	 for	 randomized	 controlled	 trials	 evaluating	 the	




trol. Cohen's d is reported.
Results: Forty-three	randomized	controlled	trials	(RCTs)	were	selected,	and	32	RCTs	













may not be as effective in comorbid subthreshold depression. Baseline depression 
and	HbA1c	scores	modify	the	treatment	effect.	Based	on	the	findings,	we	provide	
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1  | SUMMATIONS
This	 systematic	 review	 and	 meta-analysis	 exploring	 psychother-
apeutic,	 pharmacologic,	 and	 other	 interventions	 shows	 beneficial	




treatments were effective for glycemic control.
Effective	interventions	in	comorbid	depressive	disorder	may	not	
be as effective in comorbid subthreshold depression.
2  | LIMITATIONS
Most of the selected studies did not meet all criteria to reduce the 
risk of bias and not all provided sufficient data to be included in the 
meta-analysis.
Further,	some	treatments	were	only	evaluated	in	a	single	RCT.
There	 is	a	 scarcity	of	data	 from	many	 low-	and	middle-income	
countries.
3  | INTRODUC TION
No	 international	 consensus	exists	 to	guide	 treatment	of	 comorbid	
depression	in	diabetes.	Nonetheless,	over	the	last	three	decades,	cli-
nicians have been seeing increasing numbers of patients with comor-
bid	depression	of	various	severity	in	diabetes	(Khaledi	et	al.,	2019;	
Zheng	et	al.,	2018)	due	to	the	exploding	prevalence	of	both	diabe-
tes	and	depression	 (GBD	Disease	&	 Injury	 Incidence	&	Prevalence	
Collaborators,	2018).	This	can	amount	to	up	to	30%	depending	on	
severity of symptoms and it occurs especially where the person with 
diabetes	 has	 elevated	 HbA1c	 despite	 treatment,	 or	 frequent	 epi-
sodes	of	hypoglycemia	and	 increased	glucose	variability,	diabetes-
related	 complications,	 and	disengagement	 from	 treatments	 (Groot	
et	al.,	2001;	Lustman,	Anderson,	et	al.,	2000;	O'Connor	et	al.,	2009).	
Depression	 is	 a	 serious	 psychiatric	 disorder	 characterized	 by	 loss	




symptoms in people with diabetes can have a detrimental impact on 
engagement	with	diabetes	management	(Ciechanowski	et	al.,	2000;	
Gonzalez,	 Peyrot,	 et	 al.,	 2008)	 and	 on	 glycemic	 control	 (Lustman,	
Anderson,	et	al.,	2000)	as	well	as	on	health-related	outcomes	(e.g.,	
weight	 gain	 and	 diabetes-related	 complications)	 and	 associated	
healthcare	costs	(Black	et	al.,	2003)	As	such,	the	high	prevalence	of	





have an increased risk of depression and vice versa; the presence 
of a depressive disorder can increase the risk of metabolic diseases 
such	as	diabetes	(Renn	et	al.,	2011)	and	there	is	an	association	be-
tween	 depression	 and	 diabetes	 complications	 (Groot	 et	 al.,	 2001;	
Van	Steenbergen-Weijenburg	et	al.,	2011).
Evidence	is	growing	to	suggest	that	depression	may	play	a	role	in	
the pathogenesis of diabetes in a number of ways. Depression may 
be	a	consequence	of	similar	environmental	factors	that	govern	glu-
cose	metabolism,	and	can	also	independently	influence	nutrition	and	




sympathetic	 activity,	 and	 a	 pro-inflammatory	 state	 (Champaneri	
et	 al.,	 2010;	 Joseph	&	Golden,	 2017).	 The	 role	 of	 inflammation	 is	
particularly	 pertinent.	 Laake	 et	 al.	 (2014)	 found	 that	 increased	 in-
flammation may be involved in the pathogenesis of depression in 
people	with	type	2	diabetes,	which	in	turn	could	contribute	to	the	
increased risk of complications and mortality in this clinical popula-
tion	(Geraets	et	al.,	2020).
The relationship between depressive symptoms and poorer di-
abetes	self-care	(Gonzalez,	Safren,	et	al.,	2008)	applies	also	to	sub-
clinical	 or	 subthreshold	 depressive	 symptoms	 (Pibernik-Okanović	
et	al.,	2011)	and	not	only	to	major	depressive	disorder.	Subthreshold	
refers to those with two or more depressive symptoms who do not 
meet	the	diagnostic	criteria	for	depression	(Rodríguez	et	al.,	2012).	
Subthreshold	 depressive	 symptoms	 in	 people	 with	 diabetes	 have	
been found to be persistent but also associated with an increased 
risk	 of	 worsening	 over	 time	 (Bot	 et	 al.,	 2010;	 Nefs	 et	 al.,	 2012;	
Pibernik-Okanovic	 et	 al.,	 2008).	 Furthermore,	 an	 increased	 inci-
dence of adverse health outcomes and suboptimal metabolic control 
has been observed not only in patients with the established diagno-
sis of depression but also in those suffering subthreshold depressive 
symptoms	 (Johnson	et	al.,	2014).	This	 indicates	that	even	mild	de-
pression	is	clinically	relevant,	and	implies	that	combined	treatments	
could also be efficacious for people with diabetes and subthreshold 
depressive symptoms.
A	lack	of	a	clear	understanding	of	the	shared	origins	of	depres-
sion and diabetes means that finding the most appropriate treatment 
guidance	for	treatment	depending	on	patient	profile	and	desired	outcome,	and	dis-
cuss possible avenues for further research.
K E Y W O R D S
depression,	diabetes	mellitus,	glycemic	control,	meta-analysis,	systematic	review,	treatments
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for	 this	comorbidity	 in	 this	vulnerable	patient	group	 is	difficult.	 In	
order	 to	 optimize	 health	 outcomes,	 feasible	 and	 effective	 inter-
ventions aiming to provide benefits to both physical and mental 
health	are	 recommended	 (Baumeister	&	Bengel,	2012;	Baumeister	
et	al.,	2014;	Harkness	et	al.,	2010).	The	focus	of	 treatment	strate-
gies	 should	be	on	 the	 remission	or	 improvement	of	depression,	 in	
addition to improvement in glycemic control as a marker of diabetes 
outcome	(Petrak	et	al.,	2015).
Evidence	 shows	 that	 comorbid	 depression	 in	 diabetes	 can	 be	
treated with moderate success by psychological and pharmacolog-
ical	 interventions,	 often	 implemented	 by	 using	 collaborative	 care	
(Katon,	Von	Korf,	et	al.,	2004)	and	stepped	care	approaches	(Stoop	
et	al.,	2015).	However,	there	is	conflicting	evidence	for	the	efficacy	
of antidepressants and psychological therapy in the improvement 
of	 glycemic	 control	 (Lustman,	 Anderson,	 et	 al.,	 2000;	 Lustman	
et	 al.,	 1997,	 1998a,	 2000b,	 2007).	 Petrak,	Herpertz,	 et	 al.	 (2015))	
claim that more research is needed to evaluate treatment of differ-
ent subtypes of depression in people with diabetes as well as the 
effectiveness of new approaches to treatment.
3.1 | Rationale and objective
A	previous	systematic	review	of	treatments	for	comorbid	depression	




sive	 disorder	 (Gonzalez,	 Safren,	 et	 al.,	 2008;	 Pibernik-Okanović	
et	al.,	2011).	We	updated	and	expanded	this	systematic	review	and	
meta-analysis	of	randomized	controlled	trials	to	provide	an	estimate	
of the effect of interventions for comorbid depressive disorder or 
subthreshold depression in type 1 diabetes and type 2 diabetes. 
The	 interventions	were	 compared	with	 care	 as	 usual	 (CAU),	wait-





This	 systematic	 review	 and	meta-analysis	 was	 performed	 in	 ac-
cordance	 with	 the	 Preferred	 Reporting	 Items	 for	 Systematic	
Reviews	 and	 Meta-Analyses	 (PRISMA)	 statement	 (Liberati	
et	 al.,	 2009).	 We	 searched	 MEDLINE,	 Embase,	 the	 Cochrane	




RCTs and reviews were checked for relevant studies that were 
not included in the databases. The search was supported by the 
Centre	for	Reviews	and	Dissemination	at	 the	University	of	York.	
The	protocol	for	this	review	is	registered	on	PROSPERO	and	can	
be found here: https://www.crd.york.ac.uk/prosp ero/displ ay_re-
cord.php?ID=CRD42	01914	7910
The final search results were restricted to studies completed be-
fore	28th	August	2019.	Inclusion	criteria	for	studies	were	that	they	
should	be	randomized	clinical	trials,	provide	a	treatment	intended	to	
have an effect on both comorbid depressive symptoms and glycemic 
control	in	type	1	diabetes	and/or	type	2	diabetes,	and	have	a	control	
arm	(e.g.,	CAU,	placebo,	WL	or	active	comparator).	The	intervention	
had to be described sufficiently in order to be classified as a psycho-
therapeutic,	 medical,	 pharmacological,	 collaborative	 care	 or	 other	
type	of	intervention.	A	glossary	providing	an	explanation	about	the	
interventions	 and	 a	 list	 of	 acronyms	are	provided	 in	 the	 appendix	
(pp	3–4).
Participants were adult patients with diabetes and comor-
bid	 depressive	 or	 subthreshold	 depression,	 which	 was	 defined	




pressive disorder or depressive symptoms were not established in 
a	systematic	manner	such	as	by	semistructured	interview	or	ques-
tionnaire	 at	 baseline.	 Studies	were	 selected	 in	 a	 two-stage	 pro-
cess.	First,	titles	and	abstracts	from	the	electronic	searches	were	
scrutinized	by	two	independent	reviewers	(SA	and	CFC).	Second,	
if	 the	 abstract	met	 inclusion	 criteria,	we	 obtained	 full	 texts	 and	
final decisions were made about study inclusion. Disagreement 






studies,	 now	 also	 including	 subthreshold	 depression	 from	 the	
search	hits.	The	extracted	data	 included:	author	and	year;	coun-
try;	 study	 type;	 sample	 size;	 age;	 baseline	 depression	measure/
diagnostic	tool;	baseline	depression	score,	baseline	glycemic	con-
trol	score,	intervention	details;	control	group,	length	of	follow-up;	
diabetes	 and	 depression	 outcomes	with	 regard	 to:	 i)	 the	 change	
in	depression	score	from	baseline	to	last	follow-up	using	any	val-
idated	self-report	measure	of	depressive	symptomatology	and	 ii)	
the change in levels of biological marker of glycemic control from 
baseline	 to	 last	 follow-up.	Assessment	of	glycemic	control	 could	
be	 using	HbA1c,	which	 provides	 an	 integrated	measure	 of	mean	
blood	glucose	levels	over	the	last	6–8	weeks,	or	FBG,	which	gives	
an indication of the blood glucose concentration at the moment 
of	assessment.	If	both	were	reported,	we	used	the	HbA1c to cal-
culate	 a	 standardized	mean	 difference.	 The	 difference	 in	means	
of each outcome was the primary measure within each study. 
Additional	outcomes	on	adherence	to	recommendations	of	health-
care	providers	with	regard	to	self-care	behaviors	were	extracted	
if	 reported.	 Authors	 were	 approached	 for	 additional	 data	 when	
questions	arose.
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4.1 | Risk-of-bias assessment
The	Cochrane	 risk-of-bias	 tool	 (McGuire	 et	 al.,	 1998)	was	used	 to	
assess	random	sequence	generation	(selection	bias),	allocation	con-








limited	 blinding	 procedures	 were	 not	 excluded	 from	 the	 analysis.	
GRADE	 assessments	were	made	 (Guyatt	 et	 al.,	 2008)	 to	 give	 the	







studies reporting on depression versus the studies reporting on 
subthreshold	 depression.	 Then,	 studies	 were	 grouped	 accord-
ing	 to	 the	mode	of	 treatment	 (pharmacotherapy,	psychotherapy,	
collaborative	 care,	 online,	 phone	 and	 group	 interventions,	 exer-
cise),	depression	severity	 (both	as	depression	scores	at	baseline,	
and as classification of major depressive disorder or subthresh-
old	depression),	and	depressive	or	diabetes	outcome.	Effect	sizes	
were	 calculated.	Outcomes	 from	 individual	 studies	were	 pooled	
using	 a	 random-effects	 model	 (DerSimonian	 &	 Laird,	 1986),	 as	
this approach assumes that there could be clinical and method-
ological	 heterogeneity	 that	might	 affect	 the	 findings.	All	 pooled	
analyses	were	 reported	with	95%	confidence	 intervals	 (CIs).	The	
effects	 were	 presented	 in	 terms	 of	 standardized	 effect	 sizes	
(Cohen's	d).	An	effect	 size	of	0.5	 indicates	 that	 the	mean	of	 the	
experimental	 group	 is	 half	 a	 standard	 unit	 larger	 than	 the	mean	
of	 the	 control	 group.	 It	 is	 generally	 assumed	 that	 an	 effect	 size	
of	 0.56–1.2	 represents	 a	 large	 clinical	 effect,	 while	 effect	 sizes	
of	0.33–0.55	are	moderate,	 and	effect	 sizes	of	0–0.32	are	 small	
(Lipsey	 &	 Wilson,	 1993).	 A	 meta-regression	 was	 conducted	 to	
assess	whether	 baseline	 levels	 of	 depressive	 severity	 (scores	on	























analysis in accordance with the Cochrane Handbook instructions 
for	dealing	with	heterogeneity	(Higgins	et	al.,	2019),	as	pooling	was	
not	 possible	 because	 of	 heterogeneous	 control	 groups	 (Barragán-
Rodríguez	et	al.,	2008;	Gois	et	al.,	2014;	Gulseren	et	al.,	2005;	Kang	
et	 al.,	 2015;	 Karaiskos	 et	 al.,	 2013;	 Khazaie	 et	 al.,	 2011;	 Kumar	














studies were performed in patients with diabetes as the primary or 
index	 condition,	who	 suffered	 from	 comorbid	 depressive	 disorder	
or subthreshold depression. The countries in which each study was 
conducted	are	shown	in	Figure	1.
Results are shown in Table 1. The studies reported mostly on 
type	2	diabetes,	or	on	type	1	and	type	2	diabetes	combined.
Overall	meta-analysis	in	the	RCTs	comparing	all	treatments	with	
CAU,	WL,	 or	 placebo	 for	 the	 combined	 effect	 on	 depressive	 out-
come	and	glycemic	control	showed	an	effect	size	of	0.485;	95%	CI	
0.360;	0.609,	p <	.0001	(Appendix	pp	10–12).









     |  5 of 25VAN DER FELTZ-CORNELIS ET AL.
(MDD).	 All	 treatments	 showed	 significant	 effects	 in	 terms	 of	 de-
pression	 outcomes.	 Large	 effect	 sizes	were	 found	 in	 group-based	




psychotherapy:	effect	size	0.558	(95%	CI	0.417;	0.700),	p = .0001. 
Moderate	effect	sizes	were	found	in	collaborative	care:	effect	size	
0.434	(95%	CI	0.284;	0.583),	p < .0001; and phone treatment: effect 












sive	 symptoms	 (Ebert	 et	 al.,	 2017;	 Hermanns	 et	 al.,	 2015;	 Huang	
et	al.,	2016;	Penckofer	et	al.,	2012;	Pibernik-Okanovic	et	al.,	2009,	
2015;	 Tovote	 et	 al.,	 2014;	 Zheng	 et	 al.,	 2015)	 improved	 depres-
sion	outcomes	with	an	effect	 size	of	0.360	 (95%	CI	0.204;	0.516),	
p <	 .0001	 for	 all	 treatments.	 For	 psychotherapy:	 1,131	 (95%	 CI	
0.083;	 2.178),	 p =	 .034;	 and	 for	 online	 treatment	 0.737	 (95%	 CI	
0.484;	0.990),	p <	.0001).	Group	therapy	and	psychoeducation	had	
no	 significant	 effect.	 Glycemic	 control	 outcome	 effect	 sizes	were	
significant	for	psychotherapy:	0.927	(95%	CI	0.399;	1.455),	p = .001 
and	group	therapy:	0.237	(95%	CI	0.019;	0.454),	p =	.033	(Appendix	
pp	13–14).
The	 meta-regression	 analysis	 showed	 a	 significant	 association	
(slope	0.137;	p <	.0001)	between	baseline	HbA1c	and	HbA1c as out-
come but no association with depression as outcome. High baseline 
HbA1c	was	associated	with	a	greater	reduction	in	HbA1c. There was 
a	significant	association	(slope	of	0.023;	p =	.018)	between	severity	
of depression at baseline and depression as treatment outcome; and 
between severity of depression at baseline and glycemic control as 
outcome	(slope	0.028;	p =	.005).	High	baseline	depression	score	was	
associated	with	 a	 greater	 reduction	 in	HbA1c and depressive out-
come	(Appendix	pp	15–18).
I2 values for the pooled outcomes were of moderate heteroge-





ful test of the null hypothesis that there is no effect in every study 
(Higgins	et	al.,	2019)	showed	p-value	<	.0001	(Appendix	pp.	19)	indi-
cating	that	the	interventions	were	effective.	Irrespective	of	the	scales	
used	 and	 outcomes	 measured,	 consistent	 beneficial	 effects	 were	
F I G U R E  1   Map of the world showing the location of each study included in the review
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(Continues)




Measure for depression 
classification
Intervention conditions and 
follow-up













CBT plus diabetes education 


















SDS	> 50 Antidiabetics	+ diabetic 
education + psychological 
treatment +	relaxation	and	


















SDS	≥	50 Antidiabetics	+ diabetic 
education + psychological 
























education + electromyographic 

















































BDI	≥	14 Telephone delivered CBT 




















MDD as defined by 
DSM-IV	assessed	by	
clinician	using	MINI
CBT for adherence and 




















Type 2 DM =	61%
Mean age = 53.1 
(±11.8)
BDI-II	≥	14 8-weekly	sessions	of	
Mindfulness based cognitive 
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TA B L E  1  Data	extraction	table	( 	43)
Outcome assessment; depression, 
diabetes

























BDI	≥	50%)	p<.001 in CBT group










































in depression as well as 




























depression as well as glycemic 























Diabetic foot as DM 
complication;	Inpatients.	
Improvement	in	depression	
as well as glycemic control 






















symptoms but not glycemic 
control for telephone 























Main focus on adherence. 
Significant	improvements	in	

















showed significant improvements in 
both	interventions	(p<.001).	There	
was a clinically relevant improvement 
of	26%	(MBCT)	and	29%	(CBT)	
versus.	4%	(control).
Diabetes:	HbA1c levels did not change 
significantly	after	MBCT	(p=.92)	or	
CBT	(p=.72)






depressive symptoms for 
both MBCT and CBT versus 
wait	list	control.	HbA1c	levels	
































TA B L E  1   (Continued)




Measure for depression 
classification
Intervention conditions and 
follow-up
































































































































































Classification of mood 




















































TA B L E  1   (Continued)
(Continues)
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Outcome assessment; depression, 
diabetes























Diabetes:	HbA1c levels reduced 
significantly in the intervention 
group	(−4.86)	and	were	significantly	

















































control only showed 

























between both conditions. 



















n/a Depressive symptoms but not 
glycemic control improved in 
both MgCl2 and imipramine 
groups.	No	control	group	




























both improved depression 
symptoms and glycemic 
control.	No	control	group	


























n/a Depressive symptoms and 
HbA1c	levels	but	not	FBG	
levels were significantly 
lower	in	Agomelatine	group	
compared to the sertraline 
group	at	follow-up.	No	control	




















Diabetes:	HbA1c levels significantly 
lower	for	Agomelatine	(Δ	−0.62,	
p<.001)	but	not	paroxetine	(p=.038).





group so study not included in 
meta-analysis.
MDD No No
TA B L E  1   (Continued)
(Continues)




Measure for depression 
classification
Intervention conditions and 
follow-up


































































































































































Placebo =	13.0	(9.2);	Paroxetine	=  



































TA B L E  1   (Continued)
(Continues)
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Outcome assessment; depression, 
diabetes








































improving both depression 
and	glycemic	control.	No	
























improvements in depressive 
symptoms	between	IPT	and	
sertraline.	No	significant	
effect on glycemic control 


























improve depression after 
12	weeks.	Significant	
advantage of sertraline 
over diabetes specific CBT 

























as inclusion criterion. 
Improvement	in	depression	
but not in glycemic control in 
nortriptyline versus. control. 
Nortriptyline	may	have	

















































no significant improvement 
for both outcomes at end of 
follow-up.	Depression:	MADRS	total	
score mean difference 2.50; p=.25 
(n.s.)







as inclusion criterion. 
Probably a combination 






















but not in glycemic control in 
paroxetine	versus.	placebo.
MDD No No
TA B L E  1   (Continued)
(Continues)




Measure for depression 
classification
Intervention conditions and 
follow-up






































































































































































MDD or dysthymia 
according	to	SCID
Education	about	late-life	



























TA B L E  1   (Continued)
(Continues)
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Outcome assessment; depression, 
diabetes
























scale total score mean difference 
0.7;	p=.448	(n.s.).



















total score mean difference 1.0; 
(n.s.).





depression in both sertraline 
and placebo; no difference 
between conditions. 
Significant	improvement	in	

























depressive symptoms and 
glycemic control in metformin 






















reduced in both groups. Between 
group	difference	n.s	(p=.074)
Diabetes:	HbA1c	levels	reduced,	





Psychoeducation shows no 
significant benefit for either 
depressive symptoms or 



























showed no significant 
benefits over treatment 
as usual for depressive 




















but not in glycemic control 



















but not in glycemic control 



















depression but not in glycemic 
control in collaborative care 
versus. usual care in Hispanics 
with	baseline	HbA1c	> 8
MDD No No
TA B L E  1   (Continued)
(Continues)




Measure for depression 
classification
Intervention conditions and 
follow-up






Type 2 DM =	98%
54	(±8.7)

















































PHQ scores > 10 TEAMCare	(n =	95)	collaborative	







































































PHQ9 scores 5=>23 Web-based	CBT	versus	CAU
FU:	3	months	(for	iCBT	group	
only)

















































TA B L E  1   (Continued)
(Continues)
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Outcome assessment; depression, 
diabetes



























improvements in depressive 
symptoms were observed in 
the MDDP group versus care 
as	usual,	however	these	group	


























and depressive symptoms in 


























depressive symptoms but 
not glycemic control in 



















significant treatment effect found for 
HbA1C	levels	(p >.05).
n/a Significant	improvement	in	
































improvement in depressive 



























improvement in depressive 
symptoms but not glycemic 
control	in	Web-based	CBT	
group versus care as usual. 
No	follow-up	data	for	care	as	
































depressive symptoms but not 
glycemic	control	in	SWEEP	
psychoeducation group 
compared to control group.
Sub No No
TA B L E  1   (Continued)
(Continues)
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findings	from	our	meta-analysis	enable	us	to	tentatively	propose	a	
flowchart	to	guide	treatment	choice,	based	upon	the	clinical	profile	






tion;	 unclear	 reporting	 about	 attrition	 rates	 and	 intention-to-treat	
(ITT)	analysis.	Furthermore,	one	study	had	low	rates	of	compliance	
with the intervention under study and unclear reporting about the 
numbers	of	compliant	participants	(Brouwer	et	al.,	2019);	ten	stud-
ies	 used	 small	 underpowered	 samples,	 despite	 otherwise	 being	
of	 seemingly	 adequate	 quality.	 Details	 of	 the	 risk-of-bias	 assess-
ment	 for	 included	 trials	 are	 provided	 in	 the	 appendix	 (pp	 4–7).	 A	
sensitivity	 analysis	 in	 the	 16	 studies	 (Baumeister	&	Bengel,	 2012;	
Begg,	1994;	Beydoun	&	Wang,	2010;	Biostat,	2005;	Bot	et	al.,	2010;	
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on both the diabetes and depression outcomes. Column 8 describes the conclusions drawn from the study. Column 9 indicates whether the study  
focused	on	participants	with	depressive	disorder	or	clinically	significant	symptoms	(as	noted	by	MDD)	or	subthreshold	disorder	(sub).	Columns	10	 
and	11	show	whether	the	intervention	included	an	intervention	component	or	focus	on	adherence,	respectively.	The	number	of	trials	and	participants	 
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Higgins	et	al.,	2019;	Johnson	et	al.,	2014;	Nefs	et	al.,	2012;	Pibernik-
Okanović	 et	 al.,	 2011;	 Pibernik-Okanovic	 et	 al.,	 2008;	 Rodríguez	
et	 al.,	 2012;	 Simson	 et	 al.,	 2008)	 with	 low	 risk	 of	 bias	 however	
showed	a	similar	effect	size:	0.402	(95%	CI	0.271;0.533),	p < .0001 
on	 the	 combined	measures	outcome,	 compared	with	0.485	 in	 the	
original	analysis.	 I2	was	47,	which	shows	that	focusing	on	 low	risk-
of-bias	 studies	 provides	 similar	 results	 but	 reduces	 heterogeneity	
levels	(Appendix	pp.	20).	A	Begg	funnel	plot	test	for	publication	bias	
with observed and imputed studies showed no small study effect 
(Appendix	pp	21).
6  | DISCUSSION
This	 systematic	 review	 and	 meta-analysis	 shows	 beneficial	 treat-
ment effects for comorbid depression in type 1 and type 2 diabetes 
Outcome assessment; depression, 
diabetes
























PHQ9 scores mean difference =	−1.7	
[95%	CI	0.2–3.2]	(p =	.023).
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of technological developments and increase in accessibility to the 
internet,	 treatments	delivered	online	or	using	mobile	 technologies	
have	increased	in	recent	years.	For	example,	many	psychotherapies	
such as CBT can now be delivered online. This is particularly useful 
for people with diabetes given the propensity for poor health out-





Panagioti	 et	 al.,	 2016;	 Tully	 &	 Baumeister,	 2015).	 There	 are	 large	
differences between treatment effects for different interventions 
in	 terms	 of	 diabetes	 and	 depression	 outcomes.	 All	 interventions	




effect	 sizes	 of	 such	 treatments	 for	 glycemic	 control	were	 large	 in	
case	of	pharmacological	 treatment,	 group-based	 therapy	 and	psy-
chotherapy,	smaller	for	collaborative	care,	and	not	effective	at	all	in	
case	of	exercise,	online	treatment	and	phone	treatment.	The	finding	










F I G U R E  2  Forest	plot	showing	results	of	meta-analysis	of	studies	of	depressive	disorder	with	depression	as	outcome,	grouped	by	
treatment. CBT =	cognitive	behavioral	therapy;	BA	=	behavioral	activation;	EX	=	add-on	exercise;	PT	=	psychological	treatment	(counseling);	
SPT	= supportive psychotherapy
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F I G U R E  3  Forest	plot	showing	results	of	meta-analysis	of	studies	of	depressive	disorder	on	glycemic	control	grouped	by	treatment.	
CBT =	cognitive	behavioral	therapy;	BA	=	behavioral	activation;	EX	=	add-on	exercise	PT	=	psychological	treatment	(counseling)
F I G U R E  4  Flowchart	showing	treatment	recommendations	for	comorbid	depression	in	diabetes
Diabetes with 
elevated HbA1c
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type 2 diabetes).  
Group-based therapy. 




Psychotherapy or online treatment to 
primarily address MDD symptoms.
Psychotherapy to address both depression 
and glycaemic control. 
Consider Meormin in type 2 diabetes
Monitoring is sufficient. 
Collaborave care  
Phone Treatment
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suboptimal	in	people	with	diabetes	(Koopmans	et	al.,	2009),	and	this	
may	be	worse	 in	case	of	comorbid	depression	 (Katon	et	al.,	2010;	
Lysy	 et	 al.,	 2008).	 As	 the	 findings	 in	 this	meta-analysis	were	 only	
based	on	one	study	(Groot	et	al.,	2019)	on	exercise,	further	research	
is	needed.	It	would	be	of	interest	to	assess	what	the	additional	effect	
of	 an	exercise	 intervention	embedded	 into	 treatment	 for	diabetes	
and	depression	may	be.	This	should	be	explored	in	further	research	
as	well	as	the	effect	of	exercise	as	stand-alone	intervention.
This review also shows that interventions that are effective in 
depressive disorder may not be as effective in subthreshold depres-
sion.	 In	 this	group,	psychotherapy	and	online	 treatment	had	 large,	
significant	 effect	 sizes	 on	 depressive	 symptoms,	 but	 group	 ther-
apy	 and	psychoeducation	were	not	 effective.	 Looking	 at	 glycemic	
control	 as	 an	 outcome,	 psychotherapy	 had	 a	 large,	 significant	 ef-
fect	and	group-based	therapy	had	a	small,	significant	effect,	while	
online treatment and psychoeducation had no significant effect at 
all.	Consequently,	the	preferred	treatment	for	both	depression	and	
glycemic control in comorbid subthreshold depression would be 
psychotherapy.
The finding that psychoeducation is not more effective than 
CAU	in	subthreshold	depression,	both	for	depression	outcome	and	
glycemic	 control,	 is	 an	 important	 finding	 as	 in	 stepped	 care	mod-
els,	 psychoeducation	 has	 been	 suggested	 as	 a	 first	 step	 in	 diabe-
tes-related	 distress	 or	 subthreshold	 depressive	 symptoms	 (Huang	
et	al.,	2013).	Furthermore,	psychoeducation	was	supposed	to	be	a	
good	start	for	improving	self-management	and	in	that	way	improv-
ing glycemic control. This line of thought is not supported by our 
results.	 Also,	 the	 finding	 that	 group	 therapy	 is	 highly	 effective	 in	
depressive	disorder,	but	not	in	subthreshold	depression,	might	sug-
gest that patients with subthreshold depression might benefit more 
from individual treatment tailored to their specific needs rather than 
from	group	participation,	something	that	has	been	suggested	earlier	
(Huang	et	al.,	2013).	Treatment	of	comorbid	subthreshold	depressive	
disorder could be psychotherapy both in patients with elevated or 
normal	HbA1c. The latter group might also benefit from online treat-
ment.	If	glycemic	control	is	a	target,	our	analysis	shows	that	it	makes	





agement.	 Although	 effect	 sizes	 for	 some	 other	 treatment	 modes	
are	 found	 to	 be	 larger	 in	 our	 meta-analysis,	 none	 of	 those	 were	
evaluated	in	patients	with	such	a	complex	and	multimorbid	profile,	







panding field of evaluation of medicines that are normally prescribed 
for physical conditions for their effect in treatment of depression 
(Arteaga-Henríquez	et	al.,	2019;	Che	et	al.,	2018;	Köhler	et	al.,	2014).	
Further	research	could	explore	the	mechanism	for	metformin	in	im-
provement of depression in diabetes.
Our	 study	has	 several	 strengths.	 First,	we	 included	data	with-
out language restriction from studies identified by a comprehensive 
search	 of	 the	 published	 literature.	We	 included	 studies	 exploring	
the	effect	of	treatment	in	subthreshold	depression.	Our	sensitivity	





differentiated the treatment effect on depressive outcomes versus 
glycemic	control,	and	by	performing	meta-regression	we	showed	the	
influence of baseline depression severity on both depression out-
come	and	glycemic	control,	whereas	baseline	HbA1c	only	influenced	
glycemic control as an outcome. This combination of findings en-
abled us to provide clinicians with innovative guidance about which 
interventions	 may	 suit	 best,	 depending	 on	 patient	 profile.	 These	




studies	did	not	meet	 all	 criteria	 to	 reduce	 risk	of	bias,	mostly	due	
to unclear reporting and to small samples. Despite our efforts to 
contact	 authors	 for	missing	data,	we	were	unable	 to	 include	 such	
data	in	three	studies	due	to	lack	of	response	(Ell	et	al.,	2011;	Petrak,	
Herpertz,	et	al.,	2015;	van	der	Sluijs	et	al.,	2018),	which	may	have	to	




on adherence as an outcome of treatment could not be performed 
because	 of	 insufficient	 data	 (Appendix	 pp.	 22).	 Third,	 some	 treat-
ments	were	only	evaluated	in	one	RCT.	This	probably	reflects	that,	
although many of these “new treatments” have been used for some 
time	and	have	been	 felt	 to	be	useful	by	patients	and	clinicians,	 at	
least	 in	primary	care,	researchers	had	not	actively	examined	these	
“new”	 treatments	until	 recently.	 In	view	of	 their	clinical	 relevance,	
we	emphasize	this	limitation.	We	strongly	suggest	further	research	
is	 needed	 especially	 in	 group-based	 treatment	 and	 exercise,	 that	




the	map	 in	 Figure	 1.	 The	 imbalance	 is	 of	 growing	 importance	 be-
cause	it	is	likely	that	the	low-	and	middle-income	countries	will	have	
the greatest increases of comorbidities of prevalence and incidence 
of	diabetes	and	depression.	 In	countries	 in	which	 the	attention	 to	
mental health problems is minimal or absent and the investment in 
the	care	for	diabetes	is	appropriate,	the	guidance	for	treatment	that	
we	could	deduce	from	this	systematic	 review	and	meta-analysis	 is	
particularly relevant and may improve care for comorbid depression. 
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Furthermore,	the	studies	in	this	meta-analysis	do	not	present	results	
for type 1 diabetes and type 2 diabetes separately despite the dif-
ferent types of diabetes affecting different groups of the population; 
for	example,	type	2	diabetes	tends	develop	more	commonly	in	older	
people compared with a peak incidence of type 1 diabetes in adoles-
cence and young adulthood. The lack of studies in type 1 diabetes 
alone with comorbid depression or comorbid subthreshold disorder 
is striking and research is needed to fill this gap.
A	 clearer	 understanding	 of	 the	 mechanisms	 underpinning	 why	
some treatments are more effective for patients with depressive 
disorder than for subthreshold depression and vice versa would also 
greatly benefit this area of research and for this purpose studies 
might provide more detailed information about the contents of the 
intervention.	 In	particular,	the	 idea	that	 interventions	aiming	to	 im-
prove	self-management	lead	to	better	adherence	and	better	diabetes	
and depression outcomes should be challenged in research as studies 
reporting	on	adherence	as	an	outcome	are	lacking.	Studies	are	also	
needed	 to	develop	standardized	 techniques	or	 tools	 to	help	better	
identify particular subtypes of patients taking into account their de-
pression severity and glycemic control. These suggestions will further 
aid	in	the	identification	and	personalization	of	appropriate	treatment	
plans for patients with diabetes and depression as outlined above.
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